These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 922116

  • 1. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
    Buchman VM, Svet-Maoldavsky GJ, Lichinitser MR, Mkheidze DM.
    Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
    [Abstract] [Full Text] [Related]

  • 2. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM, Lichinitser MR, Svet-Moldavskiĭ GIa, Mkheidze DM.
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [Abstract] [Full Text] [Related]

  • 3. Deoxycytidine and lethal doses of cytarabine in advanced murine leukaemia.
    Buchman VM, Svet-Moldavsky GJ, Lichinitser MR, Mkheidze DM.
    Lancet; 1977 May 14; 1(8020):1061. PubMed ID: 67527
    [No Abstract] [Full Text] [Related]

  • 4. [Effect of deoxycytidine on the efficacy of cytosine arabinoside in BALB/C mice with Rauscher erythroblastic leukemia].
    Barkhotkina MF, Bukhman VM.
    Biull Eksp Biol Med; 1980 Oct 14; 90(10):472-3. PubMed ID: 7426711
    [Abstract] [Full Text] [Related]

  • 5. Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model.
    Berek JS, Schink JC, Knox RM.
    Obstet Gynecol; 1989 Oct 14; 74(4):663-6. PubMed ID: 2797645
    [Abstract] [Full Text] [Related]

  • 6. Single versus combination chemotherapy of L1210 leukemia.
    Koza I, Balázová E, Ujházy V.
    Neoplasma; 1980 Oct 14; 27(6):691-6. PubMed ID: 7254424
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
    Presant CA, Vietti TJ, Valeriote F, Coulter DM.
    J Natl Cancer Inst; 1981 Dec 14; 67(6):1283-8. PubMed ID: 6171666
    [Abstract] [Full Text] [Related]

  • 8. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
    Avery TL, Roberts D.
    Cancer Res; 1973 Apr 14; 33(4):791-9. PubMed ID: 4696479
    [No Abstract] [Full Text] [Related]

  • 9. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR, Campbell J, Rustum YM.
    Cancer Treat Rep; 1983 Jun 14; 67(6):547-54. PubMed ID: 6190558
    [Abstract] [Full Text] [Related]

  • 10. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M, Vietti T, Valeriote F.
    Cancer Res; 1974 Feb 14; 34(2):293-7. PubMed ID: 4810905
    [No Abstract] [Full Text] [Related]

  • 11. Combined effect of cytosine arabinoside and thiopurines.
    Valeriote F, Vietti T, Edelstein M.
    Cancer Treat Rep; 1976 Dec 14; 60(12):1925-34. PubMed ID: 1026347
    [Abstract] [Full Text] [Related]

  • 12. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
    Burke PJ, Karp JE, Vaughan WP.
    J Natl Cancer Inst; 1981 Sep 14; 67(3):529-38. PubMed ID: 6944525
    [Abstract] [Full Text] [Related]

  • 13. Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
    Chabot GG, Momparler RL.
    Cancer Treat Rep; 1984 Dec 14; 68(12):1483-7. PubMed ID: 6210142
    [Abstract] [Full Text] [Related]

  • 14. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC, Trader MW, Laster WR, Schabel FM.
    Cancer Treat Rep; 1978 Sep 14; 62(9):1337-49. PubMed ID: 688277
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI, Powell W.
    Cancer Invest; 1987 Sep 14; 5(4):293-9. PubMed ID: 3664332
    [Abstract] [Full Text] [Related]

  • 16. [Selective inhibition of the primary humoral immune response in mice with a combination of deoxycytidine with Cytosar].
    Bukhman VM, Barkhotkina MF, Basieva TKh.
    Biull Eksp Biol Med; 1979 Jun 14; 87(6):569-71. PubMed ID: 465690
    [Abstract] [Full Text] [Related]

  • 17. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
    Allen TM, Mehra T, Hansen C, Chin YC.
    Cancer Res; 1992 May 01; 52(9):2431-9. PubMed ID: 1568213
    [Abstract] [Full Text] [Related]

  • 18. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
    Kline I, Woodman RJ, Gang M, Sirica A, Venditti JM, Goldin A.
    Cancer Chemother Rep; 1972 Jun 01; 56(3):327-34. PubMed ID: 19051491
    [Abstract] [Full Text] [Related]

  • 19. Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia.
    Schmid FA, Hutchison DJ, Otter GM, Stock CC.
    Cancer Treat Rep; 1976 Jan 01; 60(1):23-7. PubMed ID: 1000516
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
    Cass CE, Muzik H, Paterson AR.
    Cancer Res; 1975 May 01; 35(5):1187-93. PubMed ID: 1120308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.